Ibrance and Yesafili drug interactions - a phase IV clinical study of FDA data
Summary:
We study 104,433 people who take Ibrance (palbociclib) and Yesafili (aflibercept-jbvf). There is no drug interaction reported.
The study analyzes what interactions people have when they take Ibrance and Yesafili. It is created by eHealthMe based on reports the from the FDA, and is updated regularly.
What is Ibrance?
Ibrance has active ingredients of palbociclib. eHealthMe is studying from 104,433 Ibrance users. Check the latest studies of Ibrance.
What is Yesafili?
Yesafili has active ingredients of aflibercept-jbvf.
No report is found.
Do you take Ibrance and Yesafili?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
How the study uses the data?
The study uses data from the FDA. It is based on palbociclib and aflibercept-jbvf (the active ingredients of Ibrance and Yesafili, respectively), and Ibrance and Yesafili (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Tekturna and Novolog - a second ago
- Docetaxel and Livalo drug interactions for women aged 60+ - 6 seconds ago
- Calan vs. Trazodone Hydrochloride, side effect and effectiveness comparison - 12 seconds ago
- Drug interactions of Nicoderm Cq and Diclofenac - 13 seconds ago
- Could Menopur cause Fainting? - 13 seconds ago
- Drug interactions of Calcium and Tenormin - 13 seconds ago
- Remeron and Basal Cell Carcinoma for Men aged 60+ - 15 seconds ago
- Remeron and Rodent Ulcer for Men aged 60+ - 15 seconds ago
- Remeron and Cancer - Skin - Basal Cell for Men aged 60+ - 15 seconds ago
- Remeron and Skin Cancer - Basal Cell for Men aged 60+ - 15 seconds ago